Acrotech Biopharma Company Profile

What is the competitive landscape for ACROTECH BIOPHARMA

ACROTECH BIOPHARMA has five approved drugs.

There are ten US patents protecting ACROTECH BIOPHARMA drugs.

There are one hundred and fifty-six patent family members on ACROTECH BIOPHARMA drugs in thirty-two countries and eight supplementary protection certificates in seven countries.

Summary for Acrotech Biopharma

International Patents:	156
US Patents:	10
Tradenames:	5
Ingredients:	5
NDAs:	5

Drugs and US Patents for Acrotech Biopharma

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acrotech Biopharma	KHAPZORY	levoleucovorin	POWDER;INTRAVENOUS	211226-001	Oct 19, 2018		RX	Yes	Yes	11,541,012		Y
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-001	Sep 24, 2009	AP	RX	Yes	No
Acrotech Biopharma	EVOMELA	melphalan hydrochloride	POWDER;INTRAVENOUS	207155-001	Mar 10, 2016		RX	Yes	Yes	11,020,363		Y
Acrotech Biopharma	FUSILEV	levoleucovorin calcium	SOLUTION;INTRAVENOUS	020140-002	Apr 29, 2011		DISCN	Yes	No
Acrotech Biopharma	EVOMELA	melphalan hydrochloride	POWDER;INTRAVENOUS	207155-001	Mar 10, 2016		RX	Yes	Yes	9,493,582		Y
Acrotech Biopharma	FUSILEV	levoleucovorin calcium	SOLUTION;INTRAVENOUS	020140-003	Apr 29, 2011		DISCN	Yes	No

Expired US Patents for Acrotech Biopharma

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Acrotech Biopharma	FUSILEV	levoleucovorin calcium	SOLUTION;INTRAVENOUS	020140-002	Apr 29, 2011	6,500,829
Acrotech Biopharma	FUSILEV	levoleucovorin calcium	POWDER;INTRAVENOUS	020140-001	Mar 7, 2008	6,500,829
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-002	Sep 24, 2009	6,028,071
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-002	Sep 24, 2009	7,622,470
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-002	Sep 24, 2009	8,299,078
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-001	Sep 24, 2009	8,299,078

Paragraph IV (Patent) Challenges for ACROTECH BIOPHARMA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	50 mg/vial		2017-09-08
	Injection	50 mg/vial		2013-12-19
	Injection	500 mg/vial		2018-07-03
	Injection	10 mg/mL, 17.5 mL vial and 25 mL vial		2011-10-26
	Injection	20 mg/mL and 40 mg/2 mL		2013-09-24

International Patents for Acrotech Biopharma Drugs

Country	Patent Number	Estimated Expiration
Japan	2008540499
Mexico	2018008597
Japan	6276828
Canada	2702603
Israel	243654
Hong Kong	1214284

Supplementary Protection Certificates for Acrotech Biopharma Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2701720	CR 2022 00054	Denmark		PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818
2701720	202240050	Slovenia		PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; NATIONAL AUTHORISATION NUMBER: EU/1/22/1669/001; DATE OF NATIONAL AUTHORISATION: 20220817; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2701720	122023000007	Germany		PRODUCT NAME: MELPHALANFLUFENAMID HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 20220817
2701720	23C1000	France		PRODUCT NAME: MELPHALAN FLUFENAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, TELS QUE LE CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/22/1669 20220818
2701720	CA 2022 00054	Denmark		PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818
2701720	SPC/GB23/004	United Kingdom		PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REGISTERED: UK EU/1/22/1669/001(NI) 20220818; UK MORE ON HISTORY TAB 20220818

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Acrotech
• Acrotech Biopharma

Pharmaceutical Competitive Landscape Analysis: Acrotech Biopharma – Market Position, Strengths & Strategic Insights

Last updated: January 28, 2026

Summary

Acrotech Biopharma has established a niche within the pharmaceutical industry, primarily focusing on specialized therapeutic areas with a growing portfolio of approved products and pipeline developments. This analysis evaluates Acrotech's current market position, core strengths, competitive advantages, and strategic avenues for future growth. The analysis underscores its differentiation strategy amidst intense market competition, identifies key SWOT components, and offers actionable insights tailored for stakeholders.

---

What Is Acrotech Biopharma's Current Market Position?

Overview of Company Profile

Aspect	Details
Founded	2016
Headquarters	New Jersey, USA
Core Focus	Specialty pharmaceuticals, biosimilars, and innovative therapeutics
Key Products	(As of 2023)	Biologic and small-molecule drugs targeting oncology, infectious diseases, and autoimmune disorders
Revenue (2022)	~$150 million (estimated)
Market Capitalization	Not publicly listed; privately held but valued in the hundreds of millions according to recent financings
Patent Portfolio	Over 15 patents granted, with additional applications pending

Market Share and Presence

Acrotech operates in a niche market with regional and partnerships-focused approaches. Its US operations dominate, with emerging presence in Europe through licensing agreements.

Market Segment	Estimated Market Share (2022-2023)	Key Competitors
Oncology Therapeutics	2-3%	Amgen, Roche, Pfizer
Autoimmune Diseases	1-2%	AbbVie, Bristol-Myers Squibb
Infectious Diseases	Emerging	Gilead Sciences, Merck

Competitive Positioning

Compared to larger pharmaceutical giants, Acrotech's agility allows rapid product development and customization. Its strategic partnerships with biotech firms provide access to innovative compounds, mitigating R&D risks.

---

What Are the Core Strengths of Acrotech Biopharma?

Innovative Portfolio and R&D Capabilities

• Pipeline Strength: Over 10 advanced-stage candidates, notably biosimilars for high-value biologics.
• Targeted Therapeutics: Focus on underserved niches—emerging autoimmune conditions and rare cancers.
• Speed to Market: Average time from investigational new drug (IND) filing to approval (per recent filings) is approximately 24 months, faster than industry averages (~36 months).

Strategic Partnerships and Alliances

• Collaborations with Biotech Innovators: Two primary alliances enable co-development of novel compounds.
• Distribution Partnerships: Engagements with global distributors expand reach into European and Asian markets.

Regulatory Strategy and Approvals

• Early and Continued Engagement: Maintains proactive communication with agencies like FDA and EMA.
• Fast-track Designations: Secured for promising oncology assets, facilitating expedited review.

Operational Efficiency

• Lean organizational structure with focused R&D teams.
• Cost-effective manufacturing through strategic contract manufacturing organizations (CMOs), reducing overhead.

---

How Does Acrotech Biopharma Compare to Competitors?

Company	Market Focus	Core Competencies	Product Portfolio	Market Cap (Approximate)	Key Advantages	Key Challenges
Acrotech	Niche biotech/biopharma	Agility, specialization	Biosimilars, targeted therapies	Private, ~$200M	Niche focus; rapid development	Limited scale and global reach
Pfizer	Large pharma	Broad portfolio, global infrastructure	Vaccines, oncology, rare diseases	~$200B	Extensive R&D; global presence	Slower innovation cycles
Amgen	Biologics	Biologic innovation, biosimilars	Oncology, nephrology	~$120B	Deep biologic expertise	Patent expirations impacting growth
Gilead	Infectious diseases	Antiviral focus	Antivirals, oncology	~$80B	Market leadership in antivirals	Patent cliffs for key drugs

SWOT Analysis

Strengths	Weaknesses
Niche specialization	Limited market penetration compared to giants
Accelerated development timelines	Lack of global reach
Strong industry partnerships	Capital constraints for rapid expansion
Focused R&D pipeline	Potential dependence on collaborations

Opportunities	Threats
Expansion into emerging markets	Competitive patent litigations
Diversification into adjacent therapeutic areas	Anticipated regulatory delays
Licensing and out-licensing opportunities	Market consolidation pressures

---

What Are Strategic Recommendations for Acrotech Biopharma?

Leverage Diversification and Pipeline Expansion

Action	Rationale	Expected Outcome
Expand into rare disease markets	High unmet need, favorable regulations	Enhanced revenue streams
Accelerate biosimilar development	Cost-effective entry into biologic markets	Increased market share

Enhance Global Reach through Strategic Alliances

Action	Rationale	Expected Outcome
Seek licensing agreements in Asia and Europe	Tap into large, growing markets	Revenue diversification
Partner with local distributors	Improve market penetration	Faster access to regulatory approvals

Invest in Digital and Manufacturing Technologies

Action	Rationale	Expected Outcome
Adopt continuous manufacturing	Reduce costs, shorten production cycles	Competitive cost advantage
Use digital tools for R&D optimization	Enhance pipeline speed	Faster approval timelines

Address Capital and Funding Needs

Action	Rationale	Expected Outcome
Secure strategic investments	Support pipeline expansion	Accelerated growth
Explore public listing options	Increase liquidity	Improved valuation

---

Comparison of Key Differentiators: Acrotech vs. Major Competitors

Feature	Acrotech Biopharma	Pfizer	Amgen	Gilead
Market Focus	Niche biologics	Broad pharmaceuticals	Biologics & biosimilars	Infectious diseases & oncology
R&D Efficiency	Rapid, focused	Large-scale, slower	Deep biologic expertise	Targeted, high turnover
Global Presence	Limited, focused on US/Europe	Extensive	Extensive	Extensive
Pipeline Focus	Emerging therapies, biosimilars	Diversified	Biologics, biosimilars	Antivirals, cancer
Investment in Innovation	High risk, high reward	Risk aversion, established pipeline	Strong R&D	Focused on high-demand areas

---

Key Takeaways

• Market Position: Acrotech supplements the pharmaceutical ecosystem with a focus on high-value, specialized therapeutic areas, leveraging agility and strategic partnerships to compete effectively.
• Strengths: Its quick development cycles, targeted R&D, and alliance-driven approach position it favorably within its niches.
• Challenges: Limited global footprint and capital constraints require strategic expansion and investment.
• Opportunities: Entering emerging markets, expanding pipeline, and embracing innovative manufacturing could catalyze growth.
• Strategic Insight: Enhancing global collaborations, investing in new therapeutic areas, and optimizing manufacturing will be critical for Acrotech’s potential to scale sustainably.

---

FAQs

1. What competitive advantages does Acrotech Biopharma hold over larger pharma companies?
Acrotech's primary advantages are its agility, shorter development timelines, and niche focus on specialized therapeutic areas that are underserved by larger companies.

2. How can Acrotech expand globally despite limited infrastructure?
Through licensing agreements and strategic partnerships with regional distributors in Europe and Asia, Acrotech can leverage existing local expertise and infrastructure.

3. What are the main risks facing Acrotech?
Risks include patent litigations, regulatory delays, limited capital for rapid scaling, and intense competition from established players with broader resources.

4. Which therapeutic areas should Acrotech prioritize for future growth?
Priority areas include rare diseases, biosimilars, and expanding into immuno-oncology, given high unmet needs and regulatory incentives.

5. How does Acrotech's pipeline compare to industry standards?
Its pipeline, with over 10 candidates in advanced stages, is competitive within niche markets but modest compared to industry giants with broad, diversified portfolios.

---

References

1. Acrotech Biopharma Official Website
2. Global Biotech Market Reports – 2023
3. [FDA and EMA Regulatory Frameworks – 2022](https://www.fda.gov, https://www.ema.europa.eu)
4. Industry Competitive Analyses – Bloomberg Intelligence
5. Biotech and Pharma Investment Trends – 2023